Literature DB >> 19482022

Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration.

Johanna Heering1, Patrik Erlmann, Monilola A Olayioye.   

Abstract

The phosphatase and tensin homolog (PTEN) gene is a tumor suppressor frequently deleted or mutated in sporadic tumors of the breast, prostate, endometrium and brain. The protein acts as a dual specificity phosphatase for lipids and proteins. PTEN loss confers a growth advantage to cells, protects from apoptosis and favors cell migration. The deleted in liver cancer 1 (DLC1) gene has emerged as a novel tumor suppressor downregulated in a variety of tumor types including those of the breast. DLC1 contains a Rho GTPase activating domain that is involved in the inhibition of cell proliferation, migration and invasion. To investigate how simultaneous loss of PTEN and DLC1 contributes to cell transformation, we downregulated both proteins by RNA interference in the non-invasive MCF7 breast carcinoma cell line. Joint depletion of PTEN and DLC1 resulted in enhanced cell migration in wounding and chemotactic transwell assays. Interestingly, both proteins were found to colocalize at the plasma membrane and interacted physically in biochemical pulldowns and coimmunoprecipitations. We therefore postulate that the concerted local inactivation of signaling pathways downstream of PTEN and DLC1, respectively, is required for the tight control of cell migration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19482022     DOI: 10.1016/j.yexcr.2009.05.022

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  19 in total

1.  Tensin1 positively regulates RhoA activity through its interaction with DLC1.

Authors:  Yi-Ping Shih; Peng Sun; Aifeng Wang; Su Hao Lo
Journal:  Biochim Biophys Acta       Date:  2015-09-28

2.  Effect of FAK, DLC-1 gene expression on OVCAR-3 proliferation.

Authors:  Huina Liu; Huirong Shi; Yibin Hao; Guoqiang Zhao; Xiaofeng Yang; Yali Wang; Mei Li; Min Liu
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

3.  Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells.

Authors:  Yi-Ping Shih; Yoshikazu Takada; Su Hao Lo
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

4.  miR-29b regulates migration of human breast cancer cells.

Authors:  Chen Wang; Zhen Bian; Da Wei; Jian-guo Zhang
Journal:  Mol Cell Biochem       Date:  2011-02-26       Impact factor: 3.396

5.  DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.

Authors:  Rakesh Joshi; Lyugao Qin; Xuan Cao; Shanshan Zhong; Courtney Voss; Weiping Min; Shawn S C Li
Journal:  J Biol Chem       Date:  2019-12-05       Impact factor: 5.157

6.  DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain.

Authors:  Patrik Erlmann; Simone Schmid; Florian A Horenkamp; Matthias Geyer; Thomas G Pomorski; Monilola A Olayioye
Journal:  Mol Biol Cell       Date:  2009-08-26       Impact factor: 4.138

Review 7.  Role of oxidative stress and the microenvironment in breast cancer development and progression.

Authors:  Agnieszka Jezierska-Drutel; Steven A Rosenzweig; Carola A Neumann
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 8.  Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene.

Authors:  Nicholas C Popescu; Steve Goodison
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

9.  A phosphorylation switch controls the spatiotemporal activation of Rho GTPases in directional cell migration.

Authors:  Xuan Cao; Tomonori Kaneko; Jenny S Li; An-Dong Liu; Courtney Voss; Shawn S C Li
Journal:  Nat Commun       Date:  2015-07-13       Impact factor: 14.919

10.  Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.

Authors:  Yuqi Su; Li Lin; Jingwen Zhang; Yaqi Jiang; Changqie Pan; Li Sun; Jiangman Duan; Wangjun Liao
Journal:  Mol Med Rep       Date:  2015-08-03       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.